Clinical Trials

Clinical Trials | Information Technology

Personalized Medicine: Getting More Out of Clinical Trials

IDDI, BMS Consortium aims to establish that the GPC statistical method can complement the design, analysis and interpretation of clinical trial results

Online Exclusives Kristin Brooks, Contract Pharma 02.15.19

Breaking News | Clinical Trials | Trials & Filings

SGS to Initiate Malaria Challenge Trial in Belgium

Trial to test the efficacy of MMV’s experimental compound in killing malaria parasites in the liver before they can develop and reach the bloodstream

02.12.19

Breaking News | Clinical Trials | Industry News | Information Technology

Boehringer, IBM Explore Blockchain Technology in Clinical Trials

Aims to improve the quality of clinical trial processes and record keeping

02.12.19

NeoTX, MedImmune Announce Clinical Collaboration

To support Phase 1b/2 studies investigating ANYARA in combination with AstraZeneca's IMFINZI

02.11.19

Breaking News | Clinical Trials | CRO News | Drug Development

IQVIA Launches IQVIA Biotech

Services dedicated to emerging biopharma needs

02.04.19

Neurotrope & NCI Enter Development Agreement

To develop a Phase I clinical trial testing the safety and toxicity of Bryostatin-1 in children and young adults with CD22 + leukemia and B-cell lymphoma

02.04.19

Fortress' Caelum Enters Partnership with Alexion

To advance the development of CAEL-101 for light chain (AL) amyloidosis

01.31.19

Breaking News | Clinical Trials | Drug Development | Trials & Filings

Roche Discontinues Phase III Crenezumab Studies in Early AD

Interim analysis indicates crenezumab was unlikely to meet the primary endpoint

01.30.19

Breaking News | Clinical Trials | Industry News | QA/QC

WCG, Prudentia Enter Pharmacovigilance Alliance

Aims to deliver a comprehensive solution aimed at enhancing the quality, safety and regulatory compliance of adverse event monitoring in drug development

01.29.19

Servier, Allogene Expand Clinical CAR T Tie-up

Announces FDA clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T therapy

01.28.19

Breaking News | Clinical Trials | Collaborations & Alliances | Drug Development

Evotec Earns Second Genome Milestone

Initiates Phase II study of SGM-1019, a first-in-class oral therapeutic for the treatment of nonalcoholic steatohepatitis

01.24.19

Breaking News | Clinical Trials | CRO News | Drug Development

QPS Launches New Brand Identity

Since 1995, QPS has grown from one office headquartered in Delaware to 11 locations globally, and completed seven corporate acquisitions

01.15.19

Clinigen Extends Agreement with Accord Health

The agreement now covers Accord’s European Solid Dose Products, including those in the central nervous system, autoimmune, diabetes and anti-viral therapy areas

01.10.19

Bio News | Clinical Trials | Industry News | R&D | Trials & Filings

NeuroBo Pharmaceuticals to Initiate Phase 3 Trial

Study will evaluate the efficacy of its lead drug, NB-01, in diabetic neuropathic pain, and is set to start in Q2 of this year

01.08.19

Biologics, Proteins, Vaccines | Breaking News | Clinical Trials | CRO News | Drug Development

PAREXEL Launches Biotech Division

To support emerging biotech companies in reaching their drug development and commercialization goals

01.07.19

FDA Grants Mustang Bio ODD

For MB-102 (CD123 CAR T) for the treatment of blastic plasmacytoid dendritic cell neoplasm

12.20.18

Bio News | Clinical Trials | Industry News | R&D

Neurotrope Announces Publication of Phase 2 Alzheimer's Study

The multidose, exploratory trial was to evaluate Bryostatin-1 as a treatment of cognitive deficits in moderate to severe Alzheimer's disease

12.17.18

Alkermes, Biogen Submit NDA to FDA

For diroximel fumarate (BIIB098), a novel oral fumarate in development for the treatment of relapsing forms of multiple sclerosis

12.17.18

Breaking News | Clinical Trials | CRO News | Drug Development | Promotions & Moves

PPD Adds New Therapeutic Area Leaders

Enhances drug development capabilities in cardiovascular disease, critical care, endocrinology, metabolism and diabetes

12.13.18

AC Immune & Lilly Partner for Alzheimer's

The license and collaboration agreement is to research and develop tau aggregation inhibitor small molecules for the potential treatment of AD

12.12.18

Login

Join

FOLLOW:

Subscribe Free

Magazine

eNewsletter

Checkout